grant
Targeting heat shock factor 1 (HSF1) to increase tumor infiltrating lymphocytes in metastatic breast cancer.
Organization INDIANA UNIVERSITY INDIANAPOLISLocation INDIANAPOLIS, UNITED STATESPosted 1 Apr 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY20264T1AddressAdoptive TransferAnzataxAsotaxBasal Transcription FactorBasal transcription factor genesBody TissuesBreastBreast CancerBreast Cancer CellBreast Cancer PatientBreast NeoplasmsBreast Tumor PatientBreast TumorsBristaxolCCL5CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer Cell GrowthCancersCell BodyCell FunctionCell PhysiologyCell ProcessCellsCellular FunctionCellular PhysiologyCellular ProcessCessation of lifeChemokine (C-C Motif) Ligand 5Chemotactic CytokinesComputational toolkitD17S136EDeathDevelopmentDiseaseDisorderE0771EO771EffectivenessEligibilityEligibility DeterminationExclusionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneticGoalsHomologous Chemotactic CytokinesHumanIFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune InterferonImmune infiltratesImmune mediated therapyImmunesImmunocompetentImmunologically Directed TherapyImmunomodulationImmunotherapyInfiltrationIntercrinesInterferon GammaInterferon Type IIKnock-outKnockoutKnowledgeMGC17164Malignant Breast NeoplasmMalignant CellMalignant NeoplasmsMalignant TumorMammary CancerMammary NeoplasmsMediatingMediatorMetastasisMetastasizeMetastatic Cancer to the BreastMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the BreastMetastatic TumorMetastatic Tumor to the BreastMetastatic breast cancerMiceMice MammalsModelingModern ManMolecularMurineMusMyeloid CellsNeoplasm MetastasisOutcomePD-L1 antibodyPaclitaxelPaclitaxel (Taxol)Patient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhenotypePopulationPraxelPrimary NeoplasmPrimary TumorProcessProtocol ScreeningPublishingRANTESRegulationRoleSCYA5SIS cytokinesSIS deltaSIS-deltaSISdSecondary NeoplasmSecondary TumorSmall Inducible Cytokine A5Subcellular ProcessSystemT-Cell RANTES ProteinT-Cell Specific Protein p288T8 CellsT8 LymphocytesTCP228TaxolTaxol ATaxol KonzentratTestingTherapeuticTimeTissue imagingTissuesTranscription Factor Proto-OncogeneTranscription factor genesTreatment EfficacyTumor CellTumor ImmunityTumor VolumeTumor-DerivedTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsWorkXelodaaPD-L1aPD-L1 antibodiesanti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-PD-(L)1anti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-tumor immunityantiPD-L1antitumor immunityassess effectivenessbreast tumor cellcancer cellcancer immunitycancer metastasiscancer microenvironmentcapecitabinecheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemoattractant cytokinechemokinechemotherapyclinical developmentcohortcomputational toolboxcomputational toolscomputational toolsetcomputerized toolscytotoxic CD8 T cellscytotoxic CD8 T lymphocytedetermine effectivenessdetermine efficacydevelopmentaleffectiveness assessmenteffectiveness evaluationefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate effectivenessevaluate efficacyexamine effectivenessexamine efficacyheat-shock factor 1immune cell infiltrateimmune cell infiltration of tumorsimmune cells infiltrating the tumorimmune cells that infiltrate the tumorimmune check point therapyimmune checkpoint therapyimmune competentimmune modulationimmune regulationimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimprovedin vivoindividuals with breast cancerinfiltration of tumors by immune cellsinhibitorintervention efficacyintratumoral immune cellintratumoral immune infiltrateknock-downknockdownlFN-Gammamalignancymalignant breast tumormammary tumormetastatic breast tumormetastatic mammary cancermetastatic mammary tumormortalitymouse modelmurine modelneoplasm/cancerneoplastic cellnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachoverexpressoverexpressionpatient oriented outcomespatient populationpatients with breast cancerperson with breast cancerrecruitresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsmall molecular inhibitorsmall molecule inhibitorsocial rolestandard of caresuccesstherapeutic efficacytherapeutic responsetherapeutic targettherapy efficacytherapy responsetraffickingtranscription factortreatment responsetreatment responsivenesstumortumor cell metastasistumor growthtumor immune celltumor immune infiltratetumor infiltration of immune cellstumor microenvironmentαPD-L1αPD-L1 antibodiesαPDL1
Description preview
ABSTRACT. Metastasis is the primary cause of breast cancer deaths and many therapies for metastatic patients
are more effective when immune cells are within the tumor. However, metastatic breast tumors have less immune
cells compared to primary tumors, especially CD8+ T cells, whose absence is a predictor for worse outcomes.
This creates a problem…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click